Secondary analysis of the phase 3 TRAILBLAZER-ALZ 2 trial: in 830 donanemab-treated people with early symptomatic Alzheimer's disease, plasma p-tau217 performed suboptimally at detecting amyloid clearance on PET (<24.1 CL), with an AUC of 0.61 at 52 weeks.
Secondary analysisn = 830
Collins et al. Plasma P-tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease